Summary
Around 40% of deaths worldwide are due to bleeding, which establishes haemorrhage as the most common cause of preventable death. Early intervention is generally sought by transfusing red blood cells, plasma, and platelets at a ratio of 1:1:1; however, this can lead to increased bleeding
and death. PlasFree is tackling this unmet demand of novel therapeutic approaches for haemorrhage by developing ClearPlasma™, an innovative filtration system that extracts plasminogen from plasma, leading to an efficient treatment for massive bleeding. ClearPlasma™ also allows to reduce up
to 45% of the number of plasma units required during transfusion. PlasFree will be part of a booming global blood transfusion market valued at €6.34 billion. With the EIC support, PlasFree aims to deliver substantial global impact, for patients and healthcare systems, by accelerating the
development of ClearPlasma™ as well as scaling-up and conducting clinical validation to prove the device’s safety and efficacy.
and death. PlasFree is tackling this unmet demand of novel therapeutic approaches for haemorrhage by developing ClearPlasma™, an innovative filtration system that extracts plasminogen from plasma, leading to an efficient treatment for massive bleeding. ClearPlasma™ also allows to reduce up
to 45% of the number of plasma units required during transfusion. PlasFree will be part of a booming global blood transfusion market valued at €6.34 billion. With the EIC support, PlasFree aims to deliver substantial global impact, for patients and healthcare systems, by accelerating the
development of ClearPlasma™ as well as scaling-up and conducting clinical validation to prove the device’s safety and efficacy.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190181669 |
| Start date: | 01-02-2022 |
| End date: | 31-07-2023 |
| Total budget - Public funding: | 1 827 406,25 Euro - 1 279 184,00 Euro |
Cordis data
Original description
Around 40% of deaths worldwide are due to bleeding, which establishes haemorrhage as the most common cause of preventable death. Early intervention is generally sought by transfusing red blood cells, plasma, and platelets at a ratio of 1:1:1; however, this can lead to increased bleedingand death. PlasFree is tackling this unmet demand of novel therapeutic approaches for haemorrhage by developing ClearPlasma™, an innovative filtration system that extracts plasminogen from plasma, leading to an efficient treatment for massive bleeding. ClearPlasma™ also allows to reduce up
to 45% of the number of plasma units required during transfusion. PlasFree will be part of a booming global blood transfusion market valued at €6.34 billion. With the EIC support, PlasFree aims to deliver substantial global impact, for patients and healthcare systems, by accelerating the
development of ClearPlasma™ as well as scaling-up and conducting clinical validation to prove the device’s safety and efficacy.
Status
CLOSEDCall topic
HORIZON-EIC-2021-ACCELERATOROPEN-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
